Anubha Bajaj*

Department of Histopathology, Panjab University/A.B. Diagnostics, India

*Corresponding Author: Anubha Bajaj, Department of Histopathology, Panjab University/A.B. Diagnostics, India.

Received: June 11, 2025; Published:July 01, 2025

Abstract

Wilson disease emerges as a condition delineating augmented or toxic levels of copper deposition confined to hepatic or renal parenchyma, cornea and central nervous system. The condition is preponderantly engendered due to genomic mutation within ATP7B gene with absence or dysfunction of copper transporting ATPase enzyme.

References

1. Wilson SAK. “Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver”. Brain 34 (1912): 295-507.
2. Immergluck J and Anilkumar AC. “Wilson Disease. Stat Pearls International. Treasure Island, Florida (2025).
3. Teschke R and Eickhoff A. “Wilson Disease: Copper-Mediated Cuproptosis, Iron-Related Ferroptosis, and Clinical Highlights, with Comprehensive and Critical Analysis Update”. International Journal of Molecular Sciences 9 (2024): 4753.
4. Gromadzka G., et al. “Wilson's Disease-Crossroads of Genetics, Inflammation and Immunity/Autoimmunity: Clinical and Molecular Issues”. International Journal of Molecular Sciences 16 (2024): 9034.
5. Li S., et al. “Clinical characteristics and prognosis of early diagnosed Wilson's disease: A large cohort study”. Liver International 9 (2024): 2424-2433.
6. Jang ES., et al. “Prevalence, Incidence, and Treatment Pattern of Wilson's Disease Using National Health Insurance Data From 2010-2020, Korea”. Journal of Korean Medical Science 12 (2024): e115.
7. Alkhouri N., et al. “Wilson disease: a summary of the updated AASLD Practice Guidance”. Hepatology Communications6 (2023): e0150.
8. Schilsky ML., et al. “Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial”. The Lancet Gastroenterology and Hepatology 12 (2022): 1092-1102.
9. Linder MC. “Apoceruloplasmin: abundance, detection, formation, and metabolism”. Biomedicines 9 (2021): 233.
10. Mohr I and Weiss KH. “Biochemical markers for the diagnosis and monitoring of Wilson disease”. Clinical Biochemist Reviews 40 (2019): 59-77.
11. Mordaunt CE., et al. “Epigenomic signatures in liver and blood of Wilson disease patients include hypermethylation of liver-specific enhancers”. Epigenetics Chromatin 12 (2019): 10.
12. Image 1 Courtesy: Mediniz.com
13. Image 2 Courtesy: Science direct

Citation

Citation: Anubha Bajaj. “Hoard and Accrue-Wilson’s Disease".Acta Scientific Gastrointestinal Disorders 8.7 (2025): 01-04.

Copyright

Copyright: © 2025 Anubha Bajaj. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.